Genome-wide testing sharpens diagnosis of inherited eye conditions

A single unsolved diagnosis can follow a person for years — repeated appointments, inconclusive panels, no clear answer. New research suggests that broader genetic testing may close that gap.\n\nA study published via PubMed found that genome-wide sequencing significantly improved diagnostic rates for inherited eye conditions compared with targeted gene-panel testing. Where conventional panels test a fixed list of known variants, genome-wide approaches survey the entire genome, catching mutations that fall outside the standard panel's range.\n\nThe research found that a meaningful proportion of previously undiagnosed patients received a confirmed genetic diagnosis after genome-wide testing was applied. The study did not report a single headline figure, but the pattern across cases was consistent: broader sequencing resolved cases that panels had left open.\n\n## What this means for albinism diagnoses\n\nAlbinism is caused by variants across more than twenty genes, including OCA1 through OCA4, HPS genes associated with Hermansky-Pudlak syndrome, and GPR143, which underlies ocular albinism. The diversity of causal genes makes it one of the conditions most likely to be missed or misclassified by a panel designed around a narrower target set.\n\nThe study noted that conditions involving pigmentation and nystagmus — both hallmarks of albinism — appeared among the diagnostic categories where genome-wide testing added the most value. For people with albinism whose vision impairment has never been genetically confirmed, or whose subtype has remained unclear, this finding carries practical weight.\n\nGenetic subtype affects more than a medical record. Hermansky-Pudlak syndrome, for instance, involves platelet dysfunction and, in some forms, pulmonary fibrosis — conditions that require active monitoring and are easily missed if the underlying diagnosis stops at